|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scaggiante B, Kazemi M, Pozzato G, Dapas
B, Farra R, Grassi M, Zanconati F and Grassi G: Novel
hepatocellular carcinoma molecules with prognostic and therapeutic
potentials. World J Gastroenterol. 20:1268–1288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hassler MR and Egger G: Epigenomics of
cancer-emerging new concepts. Biochimie. 94:2219–2230. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sandoval J and Esteller M: Cancer
epigenomics: Beyond genomics. Curr Opin Genet Dev. 22:50–55. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ng EK, Lee SM, Li HY, Ngai SM, Tsui SK,
Waye MM, Lee CY and Fung KP: Characterization of tissue-specific
LIM domain protein (FHL1C) which is an alternatively spliced
isoform of a human LIM-only protein (FHL1). J Cell Biochem.
82:1–10. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morgan MJ and Madgwick AJ: The LIM
proteins FHL1 and FHL3 are expressed differently in skeletal
muscle. Biochem Biophys Res Commun. 255:245–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niu C, Liang C, Guo J, Cheng L, Zhang H,
Qin X, Zhang Q, Ding L, Yuan B, Xu X, et al: Downregulation and
growth inhibitory role of FHL1 in lung cancer. Int J Cancer.
130:2549–2556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu Y, Liu Z and Guo K: Expression of FHL1
in gastric cancer tissue and its correlation with the invasion and
metastasis of gastric cancer. Mol Cell Biochem. 363:93–99. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sakashita K, Mimori K, Tanaka F, Kamohara
Y, Inoue H, Sawada T, Hirakawa K and Mori M: Clinical significance
of loss of Fhl1 expression in human gastric cancer. Ann Surg Oncol.
15:2293–2300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li X, Jia Z, Shen Y, Ichikawa H, Jarvik J,
Nagele RG and Goldberg GS: Coordinate suppression of Sdpr and Fhl1
expression in tumors of the breast, kidney, and prostate. Cancer
Sci. 99:1326–1333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spatz A, Borg C and Feunteun J:
X-chromosome genetics and human cancer. Nat Rev Cancer. 4:617–629.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding L, Wang Z, Yan J, Yang X, Liu A, Qiu
W, Zhu J, Han J, Zhang H, Lin J, et al: Human four-and-a-half LIM
family members suppress tumor cell growth through a TGF-beta-like
signaling pathway. J Clin Invest. 119:349–361. 2009.PubMed/NCBI
|
|
13
|
Shen Y, Jia Z, Nagele RG, Ichikawa H and
Goldberg GS: SRC uses Cas to suppress Fhl1 in order to promote
nonanchored growth and migration of tumor cells. Cancer Res.
66:1543–1552. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geng J, Li X, Zhou Z, Wu CL, Dai M and Bai
X: EZH2 promotes tumor progression via regulating VEGF-A/AKT
signaling in non-small cell lung cancer. Cancer Lett. 359:275–287.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zingg D, Debbache J, Schaefer SM, Tuncer
E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y,
Bonalli M, et al: The epigenetic modifier EZH2 controls melanoma
growth and metastasis through silencing of distinct tumour
suppressors. Nat Commun. 6:60512015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li LY: EZH2: Novel therapeutic target for
human cancer. Biomedicine (Taipei). 4:12014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie CR, Li Z, Sun HG, Wang FQ, Sun Y, Zhao
WX, Zhang S, Zhao WX, Wang XM and Yin ZY: Mutual regulation between
CHD5 and EZH2 in hepatocellular carcinoma. Oncotarget.
6:40940–40952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasaki M, Yamaguchi J, Itatsu K, Ikeda H
and Nakanuma Y: Over-expression of polycomb group protein EZH2
relates to decreased expression of p16 INK4a in
cholangiocarcinogenesis in hepatolithiasis. J Pathol. 215:175–183.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paradis V: Histopathology of
hepatocellular carcinoma. Recent Results Cancer Res. 190:21–32.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Asada K, Ando T, Niwa T, Nanjo S, Watanabe
N, Okochi-Takada E, Yoshida T, Miyamoto K, Enomoto S, Ichinose M,
et al: FHL1 on chromosome X is a single-hit gastrointestinal
tumor-suppressor gene and contributes to the formation of an
epigenetic field defect. Oncogene. 32:2140–2149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding L, Niu C, Zheng Y, Xiong Z, Liu Y,
Lin J, Sun H, Huang K, Yang W, Li X and Ye Q: FHL1 interacts with
oestrogen receptors and regulates breast cancer cell growth. J Cell
Mol Med. 15:72–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Liu X, Chen Z, Huang H, Jin Y,
Kolokythas A, Wang A, Dai Y, Wong DT and Zhou X: Polycomb group
protein EZH2-mediated E-cadherin repression promotes metastasis of
oral tongue squamous cell carcinoma. Mol Carcinog. 52:229–236.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani
RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression
of E-cadherin by the polycomb group protein EZH2 in cancer.
Oncogene. 27:7274–7284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumoto M, Kawakami K, Enokida H, Toki
K, Matsuda R, Chiyomaru T, Nishiyama K, Kawahara K, Seki N and
Nakagawa M: CpG hypermethylation of human four-and-a-half LIM
domains 1 contributes to migration and invasion activity of human
bladder cancer. Int J Mol Med. 26:241–247. 2010.PubMed/NCBI
|
|
28
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
